;PMID: 9726011
;source_file_1399.mrg
;Release 0.9 of PennBioIE
;Funded by NSF ITR EIA-0205448

;0)section:[e:0..38] = [t:0..38]
;1)sentence:[e:43..255] = [t:43..255]
;2)section:[e:259..402] = [t:259..402]
;3)section:[e:406..472] = [t:406..472]
;4)sentence:[e:476..643] = [t:476..643]
;5)sentence:[e:644..915] = [t:644..915]
;6)sentence:[e:916..974] = [t:916..974]
;7)sentence:[e:975..1084] = [t:975..1084]
;8)sentence:[e:1085..1206] = [t:1085..1206]
;9)sentence:[e:1207..1275] = [t:1207..1275]
;10)sentence:[e:1276..1416] = [t:1276..1416]
;11)sentence:[e:1417..1573] = [t:1417..1573]
;12)sentence:[e:1574..1782] = [t:1574..1782]
;13)sentence:[e:1783..1980] = [t:1783..1980]
;14)section:[e:1984..2028] = [t:1984..2028]

;section 0 Span:0..38
;Mutat Res  1998 Jul 17;403(1-2):103-12
(SEC
  (FRAG (DT:[0..5] Mutat) (NNP:[6..9] Res) (CD:[11..15] 1998) (NNP:[16..19] Jul)
        (CD:[20..27] 17;403-LRB-) (CD:[27..28] 1) (HYPH:[28..29] -)
        (CD:[29..30] 2) (HYPH:[30..31] -RRB-) (CD:[31..35] :103)
        (HYPH:[35..36] -) (CD:[36..38] 12)))

;sentence 1 Span:43..255
;Mutation analyses of KRAS exon 1 comparing three different techniques:
;temporal  temperature gradient electrophoresis, constant denaturant capillary
; electrophoresis and allele specific polymerase chain reaction.
;[64..68]:gene-rna:"KRAS"
;[69..75]:variation-location:"exon 1"
;[229..239]:gene-protein:"polymerase"
(SENT
  (NP-HLN
    (NP
      (NP (NN:[43..51] Mutation) (NNS:[52..60] analyses))
      (PP (IN:[61..63] of)
        (NP (NN:[64..68] KRAS)
           (NN:[69..73] exon) (CD:[74..75] 1))))
    (VP (VBG:[76..85] comparing)
      (NP
        (NP (CD:[86..91] three) (JJ:[92..101] different)
            (NNS:[102..112] techniques))
        (::[112..113] :)
        (NP
          (NP (JJ:[114..122] temporal)
            (NML (NN:[124..135] temperature) (NN:[136..144] gradient))
            (NN:[145..160] electrophoresis))
          (,:[160..161] ,)
          (NP
            (NML (JJ:[162..170] constant) (NN:[171..181] denaturant))
            (NN:[182..191] capillary) (NN:[193..208] electrophoresis))
          (CC:[209..212] and)
          (NP
            (ADJP (NN:[213..219] allele) (JJ:[220..228] specific))
            (NN:[229..239] polymerase) (NN:[240..245] chain)
             (NN:[246..254] reaction)))))
    (.:[254..255] .)))

;section 2 Span:259..402
;Bjorheim J, Lystad S, Lindblom A, Kressner U, Westring S, Wahlberg S,
;Lindmark  G, Gaudernack G, Ekstrom P, Roe J, Thilly WG, Borresen-Dale AL.
(SEC
  (FRAG (NNP:[259..267] Bjorheim) (NNP:[268..270] J,) (NNP:[271..277] Lystad)
        (NNP:[278..280] S,) (NNP:[281..289] Lindblom) (NNP:[290..291] A)
        (,:[291..292] ,) (NNP:[293..301] Kressner) (NNP:[302..303] U)
        (,:[303..304] ,) (NNP:[305..313] Westring) (NNP:[314..316] S,)
        (NNP:[317..325] Wahlberg) (NNP:[326..328] S,) (NNP:[329..337] Lindmark)
        (NNP:[339..340] G) (,:[340..341] ,) (NNP:[342..352] Gaudernack)
        (NNP:[353..354] G) (,:[354..355] ,) (NNP:[356..363] Ekstrom)
        (NNP:[364..365] P) (,:[365..366] ,) (NNP:[367..370] Roe)
        (NNP:[371..373] J,) (NNP:[374..380] Thilly) (NNP:[381..383] WG)
        (,:[383..384] ,) (NNP:[385..393] Borresen) (HYPH:[393..394] -)
        (NNP:[394..398] Dale) (NNP:[399..401] AL) (.:[401..402] .)))

;section 3 Span:406..472
;Department of Immunology, Norwegian Radium Hospital, Oslo, Norway.
(SEC
  (FRAG (NNP:[406..416] Department) (IN:[417..419] of)
        (NNP:[420..430] Immunology) (,:[430..431] ,) (NNP:[432..441] Norwegian)
        (NNP:[442..448] Radium) (NNP:[449..457] Hospital) (,:[457..458] ,)
        (NNP:[459..463] Oslo) (,:[463..464] ,) (NNP:[465..471] Norway)
        (.:[471..472] .)))

;sentence 4 Span:476..643
;Mutations in the KRAS gene is a key event in the carcinogenesis of many human
; cancers and may serve as a diagnostic marker and a target for therapeutic 
;intervention.
;[493..497]:gene-rna:"KRAS"
(SENT
  (S
    (NP-SBJ
      (NP (NNS:[476..485] Mutations))
      (PP (IN:[486..488] in)
        (NP (DT:[489..492] the) (NN:[493..497] KRAS) (NN:[498..502] gene))))
    (VP
      (VP (VBZ:[503..505] is)
        (NP-PRD (DT:[506..507] a) (JJ:[508..511] key) (NN:[512..517] event))
        (PP (IN:[518..520] in)
          (NP
            (NP (DT:[521..524] the) (NN:[525..539] carcinogenesis))
            (PP (IN:[540..542] of)
              (NP (JJ:[543..547] many) (JJ:[548..553] human)
                  (NNS:[555..562] cancers))))))
      (CC:[563..566] and)
      (VP (MD:[567..570] may)
        (VP (VB:[571..576] serve)
          (PP (IN:[577..579] as)
            (NP
              (NP (DT:[580..581] a) (JJ:[582..592] diagnostic)
                  (NN:[593..599] marker))
              (CC:[600..603] and)
              (NP
                (NP (DT:[604..605] a) (NN:[606..612] target))
                (PP (IN:[613..616] for)
                  (NP (JJ:[617..628] therapeutic) (NN:[630..642] intervention)))))))))
    (.:[642..643] .)))

;sentence 5 Span:644..915
;In this study we have applied three different techniques for  mutation
;detection of KRAS exon 1 mutations: Allele specific polymerase chain 
;reaction (AS-PCR), temporal temperature gradient electrophoresis (TTGE) and 
;constant denaturant capillary electrophoresis (CDCE).
;[728..732]:gene-rna:"KRAS"
;[733..739]:variation-location:"exon 1"
;[767..777]:gene-protein:"polymerase"
(SENT
  (S
    (PP (IN:[644..646] In)
      (NP (DT:[647..651] this) (NN:[652..657] study)))
    (NP-SBJ (PRP:[658..660] we))
    (VP (VBP:[661..665] have)
      (VP (VBN:[666..673] applied)
        (NP
          (NP
            (NP (CD:[674..679] three) (JJ:[680..689] different)
                (NNS:[690..700] techniques))
            (PP (IN:[701..704] for)
              (NP
                (NP (NN:[706..714] mutation) (NN:[715..724] detection))
                (PP (IN:[725..727] of)
                  (NP
                    (NML (NN:[728..732] KRAS)
                       (NN:[733..737] exon) (CD:[738..739] 1))
                    (NNS:[740..749] mutations))))))
          (::[749..750] :)
          (NP
            (NP
              (NP
                (ADJP (NN:[751..757] Allele) (JJ:[758..766] specific))
                (NN:[767..777] polymerase) (NN:[778..783] chain)
                 (NN:[785..793] reaction))
              (NP (-LRB-:[794..795] -LRB-) (NN:[795..801] AS-PCR)
                  (-RRB-:[801..802] -RRB-)))
            (,:[802..803] ,)
            (NP
              (NP (JJ:[804..812] temporal)
                (NML (NN:[813..824] temperature) (NN:[825..833] gradient))
                (NN:[834..849] electrophoresis))
              (NP (-LRB-:[850..851] -LRB-) (NN:[851..855] TTGE)
                  (-RRB-:[855..856] -RRB-)))
            (CC:[857..860] and)
            (NP
              (NP
                (NML (JJ:[862..870] constant) (NN:[871..881] denaturant))
                (NN:[882..891] capillary) (NN:[892..907] electrophoresis))
              (NP (-LRB-:[908..909] -LRB-) (NN:[909..913] CDCE)
                  (-RRB-:[913..914] -RRB-)))))))
    (.:[914..915] .)))

;sentence 6 Span:916..974
;Samples from 191 sporadic  colon carcinomas were analyzed.
;[933..959]:malignancy:"sporadic  colon carcinomas"
(SENT
  (S
    (NP-SBJ-1
      (NP (NNS:[916..923] Samples))
      (PP (IN:[924..928] from)
        (NP (CD:[929..932] 191)
           (JJ:[933..941] sporadic) (NN:[943..948] colon)
           (NNS:[949..959] carcinomas))))
    (VP (VBD:[960..964] were)
      (VP (VBN:[965..973] analyzed)
        (NP-1 (-NONE-:[973..973] *))))
    (.:[973..974] .)))

;sentence 7 Span:975..1084
;AS-PCR were performed with oligonucleotides  specific for know mutations in
;codon 12 and 13 of the KRAS gene.
;[1038..1047]:variation-event:"mutations"
;[1051..1059]:variation-location:"codon 12"
;[1051..1056]...[1064..1066]:variation-location:"codon"..."13"
;[1074..1078]:gene-rna:"KRAS"
(SENT
  (S
    (NP-SBJ-2 (NN:[975..981] AS-PCR))
    (VP (VBD:[982..986] were)
      (VP (VBN:[987..996] performed)
        (NP-2 (-NONE-:[996..996] *))
        (PP-MNR (IN:[997..1001] with)
          (NP
            (NP (NNS:[1002..1018] oligonucleotides))
            (ADJP (JJ:[1020..1028] specific)
              (PP (IN:[1029..1032] for)
                (NP
                  (NP (JJ:[1033..1037] know) (NNS:[1038..1047] mutations))
                  (PP-LOC (IN:[1048..1050] in)
                    (NP
                      (NP
                        (NP
                          (NML-1 (NN:[1051..1056] codon))
                          (CD:[1057..1059] 12))
                        (CC:[1060..1063] and)
                        (NP
                          (NML-1 (-NONE-:[1063..1063] *P*))
                          (CD:[1064..1066] 13)))
                      (PP (IN:[1067..1069] of)
                        (NP (DT:[1070..1073] the) (NN:[1074..1078] KRAS)
                            (NN:[1079..1083] gene))))))))))))
    (.:[1083..1084] .)))

;sentence 8 Span:1085..1206
;In TTGE  analyses, linear ramping of the temperature were performed during 
;electrophoresis in a constant denaturant gel.
(SENT
  (S
    (PP (IN:[1085..1087] In)
      (NP (NN:[1088..1092] TTGE) (NNS:[1094..1102] analyses)))
    (,:[1102..1103] ,)
    (NP-SBJ-1
      (NP (JJ:[1104..1110] linear) (NN:[1111..1118] ramping))
      (PP (IN:[1119..1121] of)
        (NP (DT:[1122..1125] the) (NN:[1126..1137] temperature))))
    (VP (VBD:[1138..1142] were)
      (VP (VBN:[1143..1152] performed)
        (NP-1 (-NONE-:[1152..1152] *))
        (PP-TMP (IN:[1153..1159] during)
          (NP
            (NP (NN:[1161..1176] electrophoresis))
            (PP-LOC (IN:[1177..1179] in)
              (NP (DT:[1180..1181] a)
                (NML (JJ:[1182..1190] constant) (NN:[1191..1201] denaturant))
                (NN:[1202..1205] gel)))))))
    (.:[1205..1206] .)))

;sentence 9 Span:1207..1275
;CDCE analyses were performed using  fluorescin labeled PCR-products.
(SENT
  (S
    (NP-SBJ-1 (NN:[1207..1211] CDCE) (NNS:[1212..1220] analyses))
    (VP (VBD:[1221..1225] were)
      (VP (VBN:[1226..1235] performed)
        (NP-1 (-NONE-:[1235..1235] *))
        (S-MNR
          (NP-SBJ (-NONE-:[1235..1235] *))
          (VP (VBG:[1236..1241] using)
            (NP
              (ADJP (NN:[1243..1253] fluorescin) (VBN:[1254..1261] labeled))
              (NN:[1262..1265] PCR) (HYPH:[1265..1266] -)
               (NNS:[1266..1274] products))))))
    (.:[1274..1275] .)))

;sentence 10 Span:1276..1416
;Separation was achieved under constant  denaturing conditions using high
;temperature in a gel-filled capillary followed  by laser detection.
(SENT
  (S
    (NP-SBJ-1 (NN:[1276..1286] Separation))
    (VP (VBD:[1287..1290] was)
      (VP (VBN:[1291..1299] achieved)
        (NP-1 (-NONE-:[1299..1299] *))
        (PP (IN:[1300..1305] under)
          (NP (JJ:[1306..1314] constant) (VBG:[1316..1326] denaturing)
              (NNS:[1327..1337] conditions)))
        (S-MNR
          (NP-SBJ (-NONE-:[1337..1337] *))
          (VP (VBG:[1338..1343] using)
            (NP
              (NP
                (NP (JJ:[1344..1348] high) (NN:[1349..1360] temperature))
                (PP (IN:[1361..1363] in)
                  (NP (DT:[1364..1365] a)
                    (ADJP (NN:[1366..1369] gel) (HYPH:[1369..1370] -)
                          (VBN:[1370..1376] filled))
                    (NN:[1377..1386] capillary))))
              (VP (VBN:[1387..1395] followed)
                (NP (-NONE-:[1395..1395] *))
                (PP (IN:[1397..1399] by)
                  (NP-LGS (NN:[1400..1405] laser) (NN:[1406..1415] detection)))))))))
    (.:[1415..1416] .)))

;sentence 11 Span:1417..1573
;A mutated KRAS gene was found in 42/191 (22.0%) of the  samples using AS-PCR,
;in 62/191 (32.5%) using TTGE and in 66/191 (34.6%) of the  samples using
;CDCE.
;[1427..1431]:gene-rna:"KRAS"
(SENT
  (S
    (NP-SBJ-1 (DT:[1417..1418] A) (VBN:[1419..1426] mutated)
              (NN:[1427..1431] KRAS) (NN:[1432..1436] gene))
    (VP (VBD:[1437..1440] was)
      (VP
        (VP (VBN:[1441..1446] found)
          (NP-1 (-NONE-:[1446..1446] *))
          (PP-LOC=2 (IN:[1447..1449] in)
            (NP
              (NP (CD:[1450..1452] 42))
              (PP (SYM:[1452..1453] /)
                (NP (CD:[1453..1456] 191)))
              (PRN (-LRB-:[1457..1458] -LRB-)
                (NP (CD:[1458..1462] 22.0) (NN:[1462..1463] %))
                (-RRB-:[1463..1464] -RRB-))
              (PP (IN:[1465..1467] of)
                (NP (DT:[1468..1471] the) (NNS:[1473..1480] samples)))))
          (S-MNR=3
            (NP-SBJ (-NONE-:[1480..1480] *))
            (VP (VBG:[1481..1486] using)
              (NP (NN:[1487..1493] AS-PCR)))))
        (,:[1493..1494] ,)
        (VP
          (PP-LOC=2 (IN:[1495..1497] in)
            (NP
              (NP (CD:[1498..1500] 62))
              (PP (SYM:[1500..1501] /)
                (NP (CD:[1501..1504] 191)))
              (PRN (-LRB-:[1505..1506] -LRB-)
                (NP (CD:[1506..1510] 32.5) (NN:[1510..1511] %))
                (-RRB-:[1511..1512] -RRB-))))
          (S-MNR=3
            (NP-SBJ (-NONE-:[1512..1512] *))
            (VP (VBG:[1513..1518] using)
              (NP (NN:[1519..1523] TTGE)))))
        (CC:[1524..1527] and)
        (VP
          (PP-LOC=2 (IN:[1528..1530] in)
            (NP
              (NP (CD:[1531..1533] 66))
              (PP (SYM:[1533..1534] /)
                (NP (CD:[1534..1537] 191)))
              (PRN (-LRB-:[1538..1539] -LRB-)
                (NP (CD:[1539..1543] 34.6) (NN:[1543..1544] %))
                (-RRB-:[1544..1545] -RRB-))
              (PP (IN:[1546..1548] of)
                (NP (DT:[1549..1552] the) (NNS:[1554..1561] samples)))))
          (S-MNR=3
            (NP-SBJ (-NONE-:[1561..1561] *))
            (VP (VBG:[1562..1567] using)
              (NP (NN:[1568..1572] CDCE)))))))
    (.:[1572..1573] .)))

;sentence 12 Span:1574..1782
;In the TTGE and CDCE analyses the sequence of the mutant  were determined by
;comparing the electrophoretic pattern to that of known  mutations or by
;mixing the sample with known mutations prior to reanalysis.
(SENT
  (S
    (PP (IN:[1574..1576] In)
      (NP (DT:[1577..1580] the)
        (NML
          (NML (NN:[1581..1585] TTGE)
            (NML-1 (-NONE-:[1585..1585] *P*)))
          (CC:[1586..1589] and)
          (NML (NN:[1590..1594] CDCE)
            (NML-1 (NNS:[1595..1603] analyses))))))
    (NP-SBJ-2
      (NP (DT:[1604..1607] the) (NN:[1608..1616] sequence))
      (PP (IN:[1617..1619] of)
        (NP (DT:[1620..1623] the) (NN:[1624..1630] mutant))))
    (VP (VBD:[1632..1636] were)
      (VP (VBN:[1637..1647] determined)
        (NP-2 (-NONE-:[1647..1647] *))
        (PP-MNR
          (PP (IN:[1648..1650] by)
            (S-NOM
              (NP-SBJ (-NONE-:[1650..1650] *))
              (VP (VBG:[1651..1660] comparing)
                (NP (DT:[1661..1664] the) (JJ:[1665..1680] electrophoretic)
                    (NN:[1681..1688] pattern))
                (PP-CLR (TO:[1689..1691] to)
                  (NP
                    (NP (DT:[1692..1696] that))
                    (PP (IN:[1697..1699] of)
                      (NP (JJ:[1700..1705] known) (NNS:[1707..1716] mutations))))))))
          (CC:[1717..1719] or)
          (PP (IN:[1720..1722] by)
            (S-NOM
              (NP-SBJ (-NONE-:[1722..1722] *))
              (VP (VBG:[1723..1729] mixing)
                (NP (DT:[1730..1733] the) (NN:[1734..1740] sample))
                (PP (IN:[1741..1745] with)
                  (NP (JJ:[1746..1751] known) (NNS:[1752..1761] mutations)))
                (S-TMP
                  (NP-SBJ (-NONE-:[1761..1761] *))
                  (ADJP-PRD (RB:[1762..1767] prior)
                    (PP (TO:[1768..1770] to)
                      (NP (NN:[1771..1781] reanalysis)))))))))))
    (.:[1781..1782] .)))

;sentence 13 Span:1783..1980
;In a  titration experiment mixing mutant and wild-type alleles prior to PCR,
;the  sensitivity for mutation detection was shown to be 10(-2) for TTGE and
;under  optimized conditions 10(-3) for CDCE.
(SENT
  (S
    (PP (IN:[1783..1785] In)
      (NP
        (NP (DT:[1786..1787] a) (NN:[1789..1798] titration)
            (NN:[1799..1809] experiment))
        (VP (VBG:[1810..1816] mixing)
          (NP
            (NP (JJ:[1817..1823] mutant)
              (NML-1 (-NONE-:[1823..1823] *P*)))
            (CC:[1824..1827] and)
            (NP
              (NML (JJ:[1828..1832] wild) (HYPH:[1832..1833] -)
                   (NN:[1833..1837] type))
              (NML-1 (NNS:[1838..1845] alleles))))
          (S-TMP
            (NP-SBJ (-NONE-:[1845..1845] *))
            (ADJP-PRD (RB:[1846..1851] prior)
              (PP (TO:[1852..1854] to)
                (NP (NN:[1855..1858] PCR))))))))
    (,:[1858..1859] ,)
    (NP-SBJ-2
      (NP (DT:[1860..1863] the) (NN:[1865..1876] sensitivity))
      (PP (IN:[1877..1880] for)
        (NP (NN:[1881..1889] mutation) (NN:[1890..1899] detection))))
    (VP (VBD:[1900..1903] was)
      (VP (VBN:[1904..1909] shown)
        (S
          (NP-SBJ-2 (-NONE-:[1909..1909] *))
          (VP (TO:[1910..1912] to)
            (VP
              (VP (VB:[1913..1915] be)
                (NP-PRD=3 (CD:[1916..1922] 10-LRB--2-RRB-))
                (PP=4 (IN:[1923..1926] for)
                  (NP (NN:[1927..1931] TTGE))))
              (CC:[1932..1935] and)
              (VP
                (PP (IN:[1936..1941] under)
                  (NP (VBN:[1943..1952] optimized) (NNS:[1953..1963] conditions)))
                (NP-PRD=3 (CD:[1964..1970] 10-LRB--3-RRB-))
                (PP=4 (IN:[1971..1974] for)
                  (NP (NN:[1975..1979] CDCE)))))))))
    (.:[1979..1980] .)))

;section 14 Span:1984..2028
;PMID: 9726011 [PubMed - indexed for MEDLINE]
(SEC
  (FRAG (NNP:[1984..1988] PMID) (::[1988..1989] :) (CD:[1990..1997] 9726011)
        (IN:[1998..1999] -LSB-) (NNP:[1999..2005] PubMed) (HYPH:[2006..2007] -)
        (JJ:[2008..2015] indexed) (IN:[2016..2019] for)
        (NNP:[2020..2028] MEDLINE-RSB-)))
